Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pharmacological therapy for hypertrophic cardiomyopathy: what is the evidence for success?
Autore:
Ryden, L; Gadler, F;
Indirizzi:
Karolinska Hosp, Dept Cardiol, S-17176 Stockholm, Sweden Karolinska Hosp Stockholm Sweden S-17176 diol, S-17176 Stockholm, Sweden
Titolo Testata:
EUROPEAN HEART JOURNAL SUPPLEMENTS
fascicolo: L, volume: 3, anno: 2001,
pagine: L21 - L25
SICI:
1520-765X(200110)3:L<L21:PTFHCW>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
OBSTRUCTIVE CARDIOMYOPATHY; VERAPAMIL THERAPY; DOUBLE-BLIND; DISOPYRAMIDE; EXERCISE; CROSSOVER;
Keywords:
treatment; pharmacological; cardiomyopathy; hypertrophic; symptoms; evidence;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Ryden, L Karolinska Hosp, Dept Cardiol, S-17176 Stockholm, Sweden Karolinska Hosp Stockholm Sweden S-17176 7176 Stockholm, Sweden
Citazione:
L. Ryden e F. Gadler, "Pharmacological therapy for hypertrophic cardiomyopathy: what is the evidence for success?", EUR H J SUP, 3(L), 2001, pp. L21-L25

Abstract

The available experience from studies of pharmacological treatment of patients with hypertrophic cardiomyopathy was mainly gained in selected patientsamples, with severe symptoms or a complicated clinical setting. Moreover.most reports on drug efficacy are based on either acute mechanistic studies or non-controlled patient cohorts. which are usually rather restricted innumbers and followed for limited periods of time, Bearing in mind the symptomatic presentation of hypertrophic cardiomyopathy, which is sometimes highly variable and influenced to a degree by sympathetic arousal, it is understandable that a considerable placebo effect may occur when initiating any type of treatment. Considering the pathophysiology that underlies symptoms of hypertrophic cardiomyopathy, it is not surprising that the pharmacological agents that are most advocated are beta-blockers and calcium channel blockers drugs that impact on several of the factors that are responsible for the symptoms. Other compounds that may be used include antiarrhythmic drugs, of which disopyramide combining antiarrhythmic with negative inotropic properties has attracted particular interest. (C) 2001 The European Society of Cardiology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 00:00:03